Shots:

• ViiV to receive $1.25B up front which is expected in Q1’22 from Gilead along with a 3% royalty until the expiration of ViiV's US Patent No. 8,129,385 on dolutegravir in 2027 on all future US sales of Biktarvy and the bictegravir compound in other bictegravir-containing products in the future US sales
• Gilead obtains a global license to dolutegravir patent while ViiV will drop related patent litigation outside the US & settled a global patent infringement litigation b/w GSK, Shionogi & Gilead filed in Feb 2018
• Gilead’s Biktarvy is a triple combination HIV medicine containing the HIV integrase inhibitor bictegravir, tenofovir alafenamide & emtricitabine & infringes its patents for dolutegravir

Ref: ViiV Healthcare | Image: Beyond Positive